The role of product development partnerships in advancing the development of drugs for unmet needs

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 6, 2013, Pages 468-470

  Breitstein, J ^a   Spigelman, M ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; DELAMANID; MOXIFLOXACIN; NEW DRUG; PYRAZINAMIDE; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL CARE; MULTIDRUG RESISTANT TUBERCULOSIS; NEGLECTED DISEASE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; TUBERCULOSIS;

DRUG DISCOVERY; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TUBERCULOSIS;

EID: 84878221952     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.53     Document Type: Review

References (5)

1. Trouiller, P. et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359, 2188-2194 (2002).
2. Looney, W. The power of product development partnership. Pharm. Exec. 〈http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id= 739264〉 (1 September 2011).
3. Willyard, C. Neglected diseases see few new drugs despite upped investment. Nat. Med. 19, 2 (2013).
4. Ponder, E. & Melinda, M. Developing new drugs & vaccines for neglected diseases of the poor: the product developer landscape. BIO Ventures for Global Health 〈http://www.bvgh.org/LinkClick.aspx?fileticket= h6a0cJK9drg%3D&ta bid=39〉 (March 2012).
5. Woodcock, J., Griffin, J. & Behrman, R. Development of novel combination therapies. N. Engl. J. Med. 364, 985-987 (2011).